Agreement - June 30, 2020
BioArctic signs agreement with the University of Oslo
BioArctic and University of Oslo, Institute of Clinical Medicine (IKM), have signed a research collaboration agreement to increase the understanding of Apolipoprotein E (ApoE) as a drug target for Alzheimer’s disease. BioArctic will provide financial support for a two-year research position, with potential extension, and Professor Lars Nilsson at the Department of Pharmacology will be […]
Agreement - June 30, 2020
Oncology Venture signs out-license agreement
Oncology Venture has signed a definitive agreement out-licensing two clinical pipeline assets, LiPlaCis and 2X-111, to Smerud Medical Research International for further clinical and commercial development. Under the terms of the agreement, Oncology Venture (OV) will receive regulatory milestone fees of nearly US $30M plus royalties on sales for each drug payable to OV if […]
Agreement - June 24, 2020
Targovax announces positive data and a new collaboration
Targovax’s ONCOS-102 mesothelioma 12-month data demonstrate broad immune activation linked to clinical benefit and the company announces a new collaboration with Merck. Targovax has released 12-month efficacy and immunological data from the randomized phase I/II trial of ONCOS-102 in combination with standard of care chemotherapy in malignant pleural mesothelioma (MPM). Clinical development of ONCOS-102 The […]
Agreement - May 15, 2020
Affibody enters partnership with Inmagene
Under the terms of the agreement, Affibody will receive a $10 million upfront payment and is eligible to receive up to $215.5 million in additional regulatory and sales milestones, plus royalties on sales in Inmagene’s commercialization territory. Affibody and Inmagene Biopharmaceuticals have announced a strategic partnership to develop and commercialize ABY-035, a bispecific molecule targeting […]
Agreement - May 14, 2020
Lipigon signs business deal with HitGen
Lipigon Pharmaceuticals has signed a new agreement with Chinese biotech company HitGen to develop drug candidates that treat blood fat disorders and cardiovascular diseases. Lipigon, which is located at the Umeå Biotech Incubator, specializes in developing medicines for lipid-related disorders, i.e. diseases caused by irregularities when fats are processed in the body. HitGen is a […]
Agreement - March 24, 2020
Moberg Pharma enters financing agreement
Moberg Pharma enters financing agreement of up to 216 million SEK for further investments in MOB-015. Moberg Pharma has entered into a convertible note agreement with Nice & Green S.A., contingent on an authorization at an Extraordinary General Meeting. In December 2019, the company reported that the primary endpoint for MOB-015 was met in the […]
